Collectively, these findings indicate that the presence of AAAs is associated with lower mean ADA concentrations and that TDM-guided dose optimization can reduce AAA levels, restore effective ADA exposure, and improve clinical outcomes. The gene discussed is ADA; the disease is triple-A syndrome.